Polaris Group is currently conducting clinical trials on ADI-PEG 20 in combination with cisplatin in melanoma and ovarian cancer, in combination with doxorubicin in HER2 negative breast cancer, in combination with nab-paclitaxel and gemcitabine for advanced pancreatic cancer, and in combination with cisplatin and pemetrexed in malignant pleural mesothelioma and non-small cell lung carcinoma. “ADI-PEG 20 is currently being evaluated as a monotherapy for HCC in a pivotal phase 3 study.
